Navigation Links
VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
Date:8/21/2012

SINGAPORE, Aug. 21, 2012 /PRNewswire/ -- VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, announces that its subsidiary Belgian Volition has signed an agreement with the Biobank of CHU UCL Mont-Godinne, an academic hospital in Yvoir, Belgium. This is the fourth large-scale external clinical trial for VolitionRX. The trial will begin in early September, and is scheduled for completion next year. The trial will be a prospective longitudinal study including approximately 250 patients as they progress through diagnosis and treatment. The project aims to develop and clinically evaluate non-invasive blood tests for early detection and prognosis of colorectal cancer.

Patient recruitment and sampling will take place in the Gastro-Enterology and Oncology Departments of the CHU UCL Mont-Godinne Hospital. Patients with a potential digestive pathology (including a mixture of suspected colorectal cancer, polyp, inflammatory bowel disease ("IBD"), Crohn's disease and colitis) will be given a blood test alongside a colonoscopy. Samples will be taken from the following cohorts:

  • Patients with positive colonoscopy for IBD or polyp: initial sample plus a follow-up blood test
  • Patients with positive colonoscopy for cancer, and treated as follows:
    • Surgery only: initial samples followed by a further blood sample approximately one month after surgery;
    • Surgery followed by chemotherapy: initial sample followed by further samples pre and post chemotherapy treatment rounds;
    • Chemotherapy followed by surgery: initial sample followed by further samples pre and post chemotherapy treatment rounds and surgery;
  • Patients with negative colonoscopy for IBD, polyp or cancer will form an age-matched healthy control cohort.

Belgian Volition will analyze the samples using its NuQ™ kits, at its laboratory in Namur, Belgium.

Jake Micallef, Chief Scientific Officer of Belgian Volition says: "This clinical trial will be our first validation study of our NuQ blood-based tests specifically on a single cancer – colorectal cancer, which is one of the most prevalent cancers, both in Belgium and worldwide. Our aim is to distinguish between patients with cancer and those with digestive conditions presenting with similar symptoms."

Cameron Reynolds, President & CEO of VolitionRX says: "We're extremely grateful to the Walloon Region of Belgium for their support and funding, which will assist us in carrying out this study into colorectal cancer. We are pleased to be working with another first-class hospital to validate our tests – ensuring that sample collection takes place exactly as it will would be when clinically available."

About VolitionRX
VolitionRX is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.

VolitionRX's development activities are currently centered in Belgium and will be augmented by commercialization work in Singapore with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.

You can find more information about VolitionRX at our website at www.volitionrx.com, on Twitter at www.twitter.com/VolitionRX, LinkedIn at www.linkedin.com/company/1364072?trk=tyah or Facebook at www.facebook.com/volitionrx.

Forward-Looking Statements: Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE VolitionRX Limited
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SuccessEHS "Forward Together" Customer Conference Begins
2. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
3. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
4. Nouveau Life Pharmaceuticals (NOUV) to Begin Sales of Azul Instant™
5. Divine Skin To Begin Manufacturing Its OTC Pain Reliever
6. Siteman Cancer Center at Barnes-Jewish and Washington University Begins Imaging with First ViewRay System
7. K-V Pharmaceutical Class A and Class B Common Stock Begin Trading on the OTC Markets
8. Countdown Begins For AdvaMed 2012: The Medtech Conference
9. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
10. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
11. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities ... ... ... ... ...
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 ... and endovascular medical technology, today announced Food and ... a cardiac resynchronization defibrillator that provides heart failure ... (MRI) scans. Iperia devices also have remote monitoring ... (CLS) that adapts the heart rate in response ...
(Date:5/3/2016)... DPLO) announced today that it is celebrating Hepatitis Awareness Month with a campaign to honor ... story and encourage those at risk to get tested and begin the road to a ... ... ... Pharmacy, Inc.) ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... 04, 2016 , ... The National Association of Professional Women (NAPW) ... the Year Circle. She is recognized with this prestigious distinction for leadership in business. ... 850,000 members and over 200 operating Local Chapters. , “I’m pleased to welcome Barbara ...
(Date:5/3/2016)... AZ (PRWEB) , ... May 03, 2016 , ... ... NCPDP presented its 2016 Champion Award to Charles D. Pulido, R.Ph., Co-Founder ... Lee Wilkins, Pharm.D., M.S., Ph.D., Pharmacy Advisor and Health IT Specialist, Office of ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... – a web application that helps people assess their risk of developing Alzheimer’s ... app will provide users a “Risk Reduction Score™” that summarizes how their lifestyle ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... a process that selects DNA or RNA from a random library of sequences ... be used as drugs or diagnostic agents. SELEX selection is commonly performed using ...
(Date:5/3/2016)... ... May 03, 2016 , ... Elizabeth Murray has always loved walking one ... with one on her shoulder and one on her arm. But she got to ... years of mitral valve prolapse. , The valves of the heart wouldn’t close properly ...
Breaking Medicine News(10 mins):